| Subject: | FDA Issues Advisory Alert for Fentanyl Transdermal (Skin) Patches |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 25 Jul 2005 - 10:00 am |
| FDA is investigating reports of death and other serious adverse events related to narcotic overdose in patients using the fentanyl transdermal patch for pain control.
Deaths and overdoses have occurred in patients using both the brand name product Duragesic and the generic product.
Factors identified as possibly related to unintentional overdose included:
Use of high doses of the fentanyl patch and/or multiple patches (sometimes in combination with other... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Bibliography:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
